SusmedTSE:4263 -2.73%69 Median PS Value is 円0.00 as of Jul. 06, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円974.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 263 Healthcare Providers & Services companies, Susmed ranks worse than 380227.76% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Susmed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円16.349. Susmed's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is 円0.00.
As of today (2026-07-06), Susmed's share price is 円818.00. Susmed's Median PS Value is 円0.00. Therefore, Susmed's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Susmed's Median PS Value or its related term are showing as below:
TSE:4263's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Susmed (TSE:4263) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Susmed's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
818.00
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed Median PS Value Related Terms
Susmed Median PS Value Historical Data
* Premium members only.
The historical data trend for Susmed's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4263 vs VEEV, BTSG, TEM: Median PS Value Comparison
For the Health Information Services subindustry, Susmed's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Susmed's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Susmed's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円16.349.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a Median PS Value of 円0.00 as of Jul. 06, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #999999 out of 263 companies in the Healthcare Providers & Services industry.
Is Susmed's Median PS Value too high?
Susmed's current Median PS Value is 円0.00. Based on the distribution chart, Susmed ranks #999999 out of 263 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Median PS Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #999999 out of 263 companies for Median PS Value. This places Susmed in the lower half of its industry. The industry median Median PS Value is 0.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.71, based on 263 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current Median PS Value is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円974.33, compared to a current price of 円818.00 — trading 16% below its estimated fair value. The current Median PS Value is 円0.00. Susmed's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Susmed (TSE:4263), the current Median PS Value is 円0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円818.00 is trading 16% below its estimated GF Value™ of 円974.33.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
Median PS Value: 円0.00
GF Value™: 円974.33 vs. price of 円818.00 (16% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score
Get the complete analysis for TSE:4263
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
